electroCore (ECOR) Corporate presentation summary

Business overview and product portfolio

• Focuses on bioelectronic medicine and wellness, targeting multiple indications including primary headache, fibromyalgia, sleep, stress, and focus.

• Offers a range of FDA-cleared and authorized products such as gammaCore for headaches and Quell for fibromyalgia.

• Expanding into consumer wellness and human performance markets with products like Truvaga and TAC-STIM.

• Products are available through various channels including VA hospitals, eCommerce, and international markets.

• Holds a broad intellectual property portfolio with over 240 patents and applications, extending beyond 2040.

Financial performance and guidance

• Achieved $19 million in revenue in the first half of 2026, representing 35% year-on-year growth.

• Net loss improved by 17% and Adjusted EBITDA net loss improved by 26% compared to the prior year.

• Ended June 30, 2026, with $10 million in cash, cash equivalents, and marketable securities.

• Increased 2026 revenue guidance to over 30% growth versus 2025, targeting positive Adjusted EBITDA in Q3 2027.

• Revenue has grown consistently year-over-year, with guidance for continued growth in 2026.

Commercial strategy and market opportunity

• New commercial leadership and expanded sales force to diversify revenue and drive growth, especially in the VA channel.

• Redesigned sales incentives to promote cost efficiency and expanded focus beyond VA to commercial and international markets.

• Large addressable markets: $20B spent annually on chronic pain, 39M adults affected by primary headache, and 6% of US adults with fibromyalgia.

• Active revenue channels include VA hospitals, commercial clinics, eCommerce for wellness, and international markets.

• Strategic catalysts include new product launches, R&D for additional indications, and operational improvements to approach profitability.